Name: 글로벌 시장 동향
SKU: MD99
Availability: InStock

보고서 요약(국문)

보고서 개요
글로벌 조영제 시장은 2023년 62억 달러에 달했으며, 2024년부터 2031년까지 연평균 6.1%의 성장률을 보이며 2031년에는 98억 6천만 달러에 이를 것으로 예상됩니다.
조영제(또는 조영 매체)는 의료 영상에서 인체 내 구조물이나 체액의 대비를 증가시키는 역할을 합니다. 조영제는 외부 전자기파 또는 초음파를 흡수하거나 변화시키는데, 이는 방사선을 방출하는 방사성 의약품과는 다릅니다. 조영제는 영상 촬영 방식의 대비 해상도를 향상시켜 병리학적 특성 파악을 돕기 위해 개발된 화학 물질 그룹입니다. 모든 구조적 영상 촬영 방식과 모든 투여 경로에 대해 특정 조영제가 개발되었습니다.
황산바륨 조영제는 수십 년 동안 사용되어 왔으며, 위장관 검사를 위한 경구 투여 조영제로 널리 사용되고 있습니다. 일반적으로 방사선 촬영 및 투시 검사에 사용됩니다. 요오드화 조영제는 방사선 촬영, 투시 촬영, 혈관 조영술 및 CT 영상 촬영에 사용되는 주요 조영제입니다. 이들은 정맥 주사, 경구 투여, 요도 내 투여, 관절 내 투여 등 다양한 투여 경로에 사용되는 다용도 조영제입니다.
시장 동향: 성장 동력
방사선과 및 진단 센터의 증가와 방사선 및 진단 분야의 발전
전 세계 조영제 시장의 수요는 여러 요인에 의해 주도됩니다. 방사선과 및 진단 센터의 증가는 조영제 시장의 주요 성장 동력 중 하나입니다. 다양한 진단 및 방사선 시술에 대한 사람들의 인식이 높아지는 것 또한 시장 성장에 기여합니다.
헬스케어 레이디어스(Healthcare Radius)에 따르면, 인도 진단 영상 시장은 향후 5년간 연평균 성장률(CAGR) 12~15%를 기록할 것으로 예상됩니다. 이는 전 세계 CAGR인 5%보다 높은 수치입니다. 만성 질환 유병률 증가, 영상 기술 도입 확대, 고령 인구 증가 등이 시장 성장을 촉진할 것으로 예상됩니다.
만성 질환, 심혈관 질환, 유전적 돌연변이, 위장 질환의 발생률 증가는 모두 해당 산업에 긍정적인 영향을 미칠 것으로 전망됩니다. 의료 부문 지출 증가와 소비자 인식 제고 또한 영상 및 방사선 산업에 활력을 불어넣을 것입니다.
제한 요인
전 세계 조영제 시장의 주요 제한 요인 중 하나는 조영제 사용과 관련된 부작용 및 알레르기 반응입니다. 진단 과정 중 일부 환자에게서 부작용이 발생하여 신체에 부정적인 영향을 미칩니다. 미국 국립보건원(NIH)에서 발표한 자료에 따르면, 비이온성 조영제에 대한 즉각적인 반응 발생률은 0.01~0.04%(중증)에서 3%(경증)까지 다양합니다. 비이온성 조영제는 상대적으로 위험성이 낮습니다.
또 다른 제한 요인은 영상 진단 기술의 발전으로 인한 높은 비용입니다. 높은 비용으로 인해 조영제 사용은 특정 계층으로 제한됩니다.

시장 세분화 분석
전 세계 조영제 시장은 유형, 적용 분야, 방식, 최종 사용자 및 지역별로 세분화됩니다.
CT 스캔 부문은 전 세계 조영제 시장 점유율의 약 48.7%를 차지했습니다.
조영제는 CT 스캔 시술에 널리 사용됩니다. 컴퓨터 단층 촬영(CT 또는 CAT 스캔)은 특수 X선 장비와 정교한 컴퓨터 기술을 결합하여 인체의 단면 이미지(종종 슬라이스라고 함)를 수평 및 수직으로 생성하는 비침습적 진단 영상 절차입니다. 검사 대상 부위의 이러한 단면 이미지는 컴퓨터 모니터에서 검토하거나 인쇄할 수 있습니다.
CT 스캔에 사용되는 조영제의 주성분은 요오드입니다. CT 조영제는 이온성 및 비이온성 두 가지 유형이 있습니다. 현재 CT 스캔에서는 비이온성 조영제가 가장 널리 사용됩니다. 제퍼슨 방사선학에 따르면, 조영제를 사용한 CT 스캔은 뼈, 혈관 및 장기와 같은 내부 구조를 시각화하는 데 널리 사용됩니다. 조영제는 특히 종양, 혈관 질환 및 내부 출혈을 감지하는 데 유용합니다.
예를 들어, 2022년 7월 프레제니우스 카비는 미국 식품의약국(FDA)이 전국적으로 공급 부족 품목으로 지정한 이오딕사놀 주사제(USP) 출시를 시작으로 미국에서 다양한 제네릭 조영제 포트폴리오를 선보일 것이라고 발표했습니다. 이오딕사놀 주사제(USP)는 미국 FDA 승인을 받은 최초의 제네릭 등장성 이량체 요오드화 조영제로, 컴퓨터 단층 촬영(CT)과 같은 진단용 X선 영상 촬영에 사용됩니다.
시장 지역 분석
북미는 전 세계 조영제 시장 점유율의 약 49.2%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 방사선과 및 진단 센터 수 증가와 사람들의 인식 제고가 시장 성장을 견인하고 있습니다.

북미 지역에는 주요 업체들이 활동하고 있어 진단 및 방사선 시술 분야에서 발전이 이루어지고 있습니다. 장기 질환 및 복합적인 동반 질환의 발생률 증가, 그리고 개인 및 공공 의료비 상승 등의 요인이 북미 시장 성장을 촉진할 것으로 예상됩니다.
예를 들어, 2024년 1월, 케이스 웨스턴 리저브 대학교(CWRU)의 과학자들은 화학 영상 조영제를 대체할 인공지능 기반 기술 개발 연구를 시작했습니다. CWRU는 최근 미국 국립과학재단(NSF)으로부터 4년간 112만 5천 달러의 연구비를 지원받아 이 연구에 박차를 가하고 있습니다. 이들은 가돌리늄과 같은 물질을 주입하지 않고도 CT, MR, X선 검사 시 영상을 개선할 수 있는 새로운 접근 방식을 개발하기 위해 노력하고 있습니다.

시장 세분화
유형별
• 바륨계 조영제
• 요오드화 조영제
• 가돌리늄계 조영제
• 미세기포계 조영제
적용 분야별
• 종양학
• 심장학
• 신경학
• 기타
영상 방식별
• X선/CT
• MRI
• 초음파
• 기타
최종 사용자별
• 병원
• 전문 클리닉
• 진단 센터
• 기타
지역별
• 북미
• 미국
• 캐나다
• 멕시코
• 유럽
• 독일
• 영국
• 프랑스
• 스페인
• 이탈리아
• 기타 유럽
• 남미
• 브라질
• 아르헨티나
• 기타 남미
• 아시아 태평양
• 중국
• 인도
• 일본
• 한국
• 기타 아시아 태평양
• 중동 및 아프리카
시장 경쟁 환경
글로벌 조영제 시장의 주요 글로벌 업체 시장 참여 기업으로는 Bayer AG, GE Healthcare, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd., Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB, Taejoon Pharma 등이 있습니다.
주요 개발 사항
• 2022년 9월, 진단 영상 분야의 혁신적인 세계적 선도 기업인 Bracco Imaging S.p.A.의 미국 자회사인 Bracco Diagnostics Inc.는 미국 식품의약국(FDA)이 새로운 고안정성 거대고리형 가돌리늄 기반 조영제(GBCA)인 가도피클레놀 주사제를 승인했다고 발표했습니다. 가도피클레놀 주사제는 현재 미국에서 사용 가능한 모든 GBCA 중 가장 높은 이완율을 나타냅니다.

• 2023년 2월, 30년 이상 MRI 분야에서 경험을 쌓아온 세계적인 의료 영상 기업 게르베(Guerbet)는 2022년 미국 식품의약국(FDA) 승인을 받은 차세대 가돌리늄 기반 조영제 엘루시렘™(Elucirem™, 가도피클레놀) 주사제의 상용 출시 및 첫 환자 투약을 발표했습니다. 게르베의 차세대 GBCA인 엘루시렘™은 고안정성 거대고리형 가돌리늄 기반 조영제(GBCA)로, 자기공명영상(MRI)에서 동종 최고 수준의 이완율을 자랑하며 2세 이상 성인 및 소아에게 사용이 허가되었습니다.

보고서 구매 이유:

• 유형, 적용 분야, 영상 방식, 최종 사용자 및 지역별 글로벌 조영제 시장 세분화 현황을 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 글로벌 조영제 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 정성적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• • 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료가 엑셀 파일로 제공됩니다.
글로벌 조영제 시장 보고서는 약 78개의 표와 그림, 그리고 181페이지 분량으로 구성될 예정입니다.
2024년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Contrast Agents Market reached US$ 6.2 billion in 2023 and is expected to reach US$ 9.86 billion by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.
A contrast agent (or contrast medium) increases the contrast of structures or fluids within the body in medical imaging. Contrast agents absorb or alter external electromagnetism or ultrasound, which differs from radiopharmaceuticals, which emit radiation. Contrast agents are a group of chemical agents developed to aid in the characterization of pathology by improving the contrast resolution of an imaging modality. Specific contrast agents have been developed for every structural imaging modality and every conceivable route of administration.
Barium sulfate contrast media have been used for many decades, and are well-established as oral agents for the examination of the GI tract. Their use is generally restricted to radiographic and fluoroscopic examinations. Iodinated contrast media are the mainstay contrast agents for use in radiographic, fluoroscopic, angiographic, and CT imaging. They are a versatile group of agents used for intravenous, oral, and other routes of administration, such as urethral and intra-articular.
Market Dynamics: Drivers
The rise and increase in the number of radiology and diagnostic centers and advancements in the field of radiology and diagnostics
The demand for the global contrast agents market is driven by multiple factors. The rise and increase in the number of radiology and diagnostic centers is one of the major driving factors in the contrast agents market. The increased awareness among people about various diagnostic and radiology procedures also leads to an increase in the market.
According to the healthcare radius, the Indian diagnostic imaging market is expected to register a compounded annual growth rate (CAGR) of 12-15 percent over the next five years. This number is greater than the global CAGR rate which is pegged at five percent. The rise in prevalence of chronic diseases, increased adoption of technologies in imaging, and a growing elderly/geriatric population are expected to boost the growth.
The increasing incidences of chronic diseases, cardiovascular disorders, genetic mutations, and GI disorders are all expected to impact the industry positively. Increased expenditure on the healthcare sector and greater consumer awareness will also give an impetus to the imaging and radiology industry.
Restraints
One of the major restraints in the global contrast agents market is the side effects and allergic reactions that are associated with the usage of contrast agents. In a few people during the diagnostic procedures, side effects are observed which causes a negative impact on the body. According to an article published by NIH, the incidence of immediate reactions to non-ionic contrast media ranges from, 0.01-0.04%(severe) to 3%(mild). Non-ionic agents are associated with less risk.
Another restraint is the high cost due to advancements in imaging procedures. The high cost limits the usage of contrast agents to certain segments of people.
Market Segment Analysis
The global contrast agents market is segmented based on type, application, modality, end-user, and region.
The segment CT scan accounted for approximately 48.7% of the global contrast agents market share
The contrast agents are widely used in the procedure of CT scans. Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body. These cross-sectional images of the area being studied can then be examined on a computer monitor or printed.
The main component of the contrast material used in the CT scan is iodine. The CT contrast agents are of two types: ionic and non-ionic. At present, in CT scans the non-ionic contrast agents are most widely used. According to Jefferson radiology, CT scans with contrast agents are widely used to visualize internal structures such as bones, blood vessels, and organs. They are particularly useful in detecting tumors, vascular diseases, and internal bleeding.
For instance, in July 2022, Fresenius Kabi announced that it would introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide. Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans.
Market Geographical Analysis
North America accounted for approximately 49.2% of the global contrast agents market share
North America region is expected to hold the largest market share over the forecast period. The increase in the number of radiology and diagnostic centers, and growing awareness among people, in this region, help to propel the market.
Due to the presence of major players in the region of North America, it has advancements in diagnostic and radiology procedures. Factors including the rising incidence of long-term sicknesses and complicated comorbidities and increasing private and authority fees are expected to gasoline market increase in the North U.S.
For instance, in January 2024, Scientists with Case Western Reserve University started researching and working on the development of an artificial intelligence-based alternative to chemical imaging contrast agents. CWRU recently scored a four-year, $1.125 million grant from the National Science Foundation to help fuel its work. They are working their best to create a new approach during CT, MR, and X-ray exams, enhancing images without injecting substances such as gadolinium.
Market Segmentation
By Type
• Barium-based contrast media
• Iodinated contrast media
• Gadolinium-based contrast medium
• Microbubble-based contrast media
By Application
• Oncology
• Cardiology
• Neurology
• Others
By Modality
• X-Ray / CT
• MRI
• Ultrasound
• Others
By End-User
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others
By Region
• North America
• The U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe
• South America
• Brazil
• Argentina
• Rest of South America
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa
Market Competitive Landscape
The major global players in the global contrast agents market include Bayer AG, GE Health care, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd., Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB, Taejoon Pharma among others.
Key Developments
• In September 2022, Bracco Diagnostics Inc., the United States (U.S.) subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), which shows the highest relaxivity compared to all the other GBCAs available today in the United States.
• In February 2023, Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022. This next-generation GBCA from Guerbet, a highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.
Why Purchase the Report?
• To visualize the global contrast agents market segmentation based on type, application, modality, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global contrast agents market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global contrast agents market report would provide approximately 78 tables, figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Modality
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing the number of radiology and diagnostic centers
4.1.1.2. Advancements in the field of diagnostics
4.1.1.3. Increase in the number of chronic diseases in the global population

5. Restraints
5.1. High cost of the contrast agents
5.2. Side effects associated with usage of contrast agents
6. Opportunity
7. Impact Analysis
8. Industry Analysis
8.1. Porter's Five Force Analysis
8.2. Supply Chain Analysis
8.3. Pricing Analysis
8.4. Regulatory Analysis
8.5. Unmet Needs
8.6. PESTEL Analysis
8.7. Patent Analysis
8.8. SWOT Analysis
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Barium based contrast media*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Iodinated contrast media
9.4. Gadolinium-based contrast media
9.5. Microbubble-based contrast media
9.6. Others
10. By Application
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Oncology*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiology
10.4. Neurology
10.5. Others
11. By Modality
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.1.2. Market Attractiveness Index, By Modality
11.2. X-Ray / CT*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. MRI
11.4. Ultrasound
11.5. Others
12. By End-User
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Specialty Clinics
12.4. Diagnostic Centers
12.5. Others
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. UK
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. South Korea
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Positioning/Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Bayer AG*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. GE Health Care
15.3. Bracco diagnostics Inc.,
15.4. Lantheus Medical Imaging
15.5. Nano Therapeutics Pvt Ltd.
15.6. Unijules Life Sciences Ltd.,
15.7. Guerbet SA
15.8. Trivitron Healthcare
15.9. Spago Nanomedical AB
15.10. Taejoon Pharma (*LIST NOT EXHAUSTIVE)
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Bayer AG, 4.	Key Developments, GE Health Care, Bracco diagnostics Inc.,, Lantheus Medical Imaging, Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd.,, Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB

표 목록 (Tables)

List of Tables

Table 1 Global Contrast Agents Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Contrast Agents Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Contrast Agents Market Value, By Modality, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Contrast Agents Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Contrast Agents Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Contrast Agents Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 8 Global Contrast Agents Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 10 Global Contrast Agents Market Value, By Modality, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 12 Global Contrast Agents Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global Contrast Agents Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Contrast Agents Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 17 North America Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 18 North America Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 19 North America Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America Contrast Agents Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 22 South America Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 23 South America Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 24 South America Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 South America Contrast Agents Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 27 Europe Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Europe Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 29 Europe Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe Contrast Agents Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Contrast Agents Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Contrast Agents Market Value, By Type, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Contrast Agents Market Value, By Application, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Contrast Agents Market Value, By Modality, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Contrast Agents Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Contrast Agents Market Value, By Country, 2022-2031 (US$ Million)

Table 41 Bayer AG: Overview

Table 42 Bayer AG: Product Portfolio

Table 43 Bayer AG: Key Developments

Table 44 GE Health care: Overview

Table 45 GE Health care: Product Portfolio

Table 46 GE Health care: Key Developments

Table 47 Bracco Diagnostics Inc.: Overview

Table 48 Bracco Diagnostics Inc.: Product Portfolio

Table 49 Bracco Diagnostics Inc.: Key Developments

Table 50 Lantheus Medical Imaging: Overview

Table 51 Lantheus Medical Imaging: Product Portfolio

Table 52 Lantheus Medical Imaging: Key Developments

Table 53 Nano Therapeutics Pvt Ltd.: Overview

Table 54 Nano Therapeutics Pvt Ltd.: Product Portfolio

Table 55 Nano Therapeutics Pvt Ltd.: Key Developments

Table 56 Unijules Life Sciences Ltd.: Overview

Table 57 Unijules Life Sciences Ltd.: Product Portfolio

Table 58 Unijules Life Sciences Ltd.: Key Developments

Table 59 Guerbet SA: Overview

Table 60 Guerbet SA: Product Portfolio

Table 61 Guerbet SA: Key Developments

Table 62 Trivitron Healthcare: Overview

Table 63 Trivitron Healthcare: Product Portfolio

Table 64 Trivitron Healthcare: Key Developments

Table 65 Spago Nanomedical AB: Overview

Table 66 Spago Nanomedical AB: Product Portfolio

Table 67 Spago Nanomedical AB: Key Developments

Table 68 Taejoon Pharma: Overview

Table 69 Taejoon Pharma: Product Portfolio

Table 70 Taejoon Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 2 Global Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 4 Global Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 5 Global Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 6 Global Contrast Agents Market Share, By Region, 2023 & 2031 (%)

Figure 7 Global Contrast Agents Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 8 Barium-based contrast media Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 9 Iodinated contrast media Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 10 Gadolinium-based contrast medium Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 11 Microbubble-based contrast media Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 12 Global Contrast Agents Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 13 Oncology Application in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 14 Cardiology Application in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 15 Neurology Application in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 16 Others Application in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 17 Global Contrast Agents Market Y-o-Y Growth, By Modality, 2023-2031 (%)

Figure 18 X-Ray / CT Modality in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 19 MRI Modality in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 20 Ultrasound Modality in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 21 Global Contrast Agents Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 22 Hospitals End-User in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 23 Specialty Clinics End-User in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 24 Diagnostic Centers End-User in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 25 Others End-User in Global Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 26 Global Contrast Agents Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 27 North America Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 28 North America Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 29 North America Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 30 North America Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 31 North America Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 32 North America Contrast Agents Market Share, By Country, 2023 & 2031 (%)

Figure 33 South America Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 34 South America Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 35 South America Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 36 South America Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 37 South America Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 38 South America Contrast Agents Market Share, By Country, 2023 & 2031 (%)

Figure 39 Europe Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 40 Europe Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 41 Europe Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 42 Europe Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 43 Europe Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 44 Europe Contrast Agents Market Share, By Country, 2023 & 2031 (%)

Figure 45 Asia-Pacific Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 46 Asia-Pacific Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 47 Asia-Pacific Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 48 Asia-Pacific Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 49 Asia-Pacific Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 50 Asia-Pacific Contrast Agents Market Share, By Country, 2023 & 2031 (%)

Figure 51 Middle East and Africa Contrast Agents Market Value, 2022-2031 (US$ Million)

Figure 52 Middle East and Africa Contrast Agents Market Share, By Type, 2023 & 2031 (%)

Figure 53 Middle East and Africa Contrast Agents Market Share, By Application, 2023 & 2031 (%)

Figure 54 Middle East and Africa Contrast Agents Market Share, By Modality, 2023 & 2031 (%)

Figure 55 Middle East and Africa Contrast Agents Market Share, By End-User, 2023 & 2031 (%)

Figure 56 Bayer AG: Financials

Figure 57 GE Health care: Financials

Figure 58 Bracco Diagnostics Inc.: Financials

Figure 59 Lantheus Medical Imaging: Financials

Figure 60 Nano Therapeutics Pvt Ltd.: Financials

Figure 61 Unijules Life Sciences Ltd.: Financials

Figure 62 Guerbet SA: Financials

Figure 63 Trivitron Healthcare: Financials

Figure 64 Spago Nanomedical AB: Financials

Figure 65 Taejoon Pharma: Financials

세계 조영제 시장 – 2024-2031년

Global Contrast Agents Market - 2024-2031